Biological Activity of a 4-Hydroxy-Furanyl-Benzamide Derivative on Heart Failure

Drug Res (Stuttg). 2023 Mar;73(3):175-183. doi: 10.1055/a-1855-1412. Epub 2022 Dec 23.

Abstract

Background: There are studies that suggest that some benzamide derivatives may exert effects on heart failure; however, their molecular mechanism is not very clear.

Objective: The aim of this research was to evaluate the biological activity of a 4-hydroxy-furanyl-benzamide derivative against heart failure translated as area infarct.

Methods: Biological activity produced by 4-hydroxy-furanyl-benzamide derivative against heart failure was determinate using an ischemia-reperfusion injury model. In addition, the effects exerted by the 4-hydroxy-furanyl-benzamide derivative on left ventricular pressure (LVP) was evaluated in the absence or presence of some drugs such as yohimbine, butaxamine, methoctramine and L-NAME using a model of rat heart isolated.

Results: The results showed that 4-hydroxy-furanyl-benzamide derivative decrease both infarct area and LVP. However, the effect produced by 4-hydroxy-furanyl-benzamide derivative on LVP was inhibited in the presence of both methoctramine and L-NAME.

Conclusions: All these data suggest that biological activity produced by 4-hydroxy-furanyl-benzamide derivative on left ventricular pressure is through of both M2-muscarinic receptor and nitric oxide synthase enzyme activation. It is important to mention that this phenomenon results as a decrease of both infarct area and heart failure.

MeSH terms

  • Animals
  • Benzamides / pharmacology
  • Benzamides / therapeutic use
  • Heart
  • Heart Failure* / drug therapy
  • Infarction
  • Myocardial Reperfusion Injury*
  • NG-Nitroarginine Methyl Ester
  • Rats

Substances

  • methoctramine
  • NG-Nitroarginine Methyl Ester
  • Benzamides